It has been proposed that inhibition of TRPV4 could have therapeutic benefits in several respiratory conditions, such as chronic heart failure, hypoxia-induced pulmonary hypertension, acute lung injury, chronic obstructive pulmonary disease and cough [48–51]. This evidence concerns the gene TRPV4 and congestive heart failure.